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and progenitor cells (HSPCs) has demonstrated remarkable
clinical success in gene therapy for monogenic hematopoietic
disorders. However, little attention has been paid to enhance-
ment of culture and transduction conditions to achieve reliable
effects across patient and disease contexts and to maximize
potential vector usage and reduce treatment cost. We systemat-
ically tested three HSPC culture media manufactured to cGMP
and eight previously described transduction enhancers (TEs) to
develop a state-of-the-art clinically applicable protocol. Six TEs
enhanced lentiviral (LV) and ﬁve TEs facilitated alpharetroviral
(ARV) CD34+ HSPC transduction when used alone. Combina-
torial TE application tested with LV vectors yielded more
potent effects, with up to a 5.6-fold increase in total expression
of a reporter gene and up to a 3.8-fold increase in VCN. Appli-
cation of one of the most promising combinations, the polox-
amer LentiBOOST and protamine sulfate, for GMP-compliant
manufacturing of a clinical-grade advanced therapy medicinal
product (ATMP) increased total VCN by over 6-fold, with no
major changes in global gene expression proﬁles or inadvertent
loss of CD34+CD90+ HSPC populations. Application of these
deﬁned culture and transduction conditions is likely to signif-
icantly improve ex vivo gene therapy manufacturing protocols
for HSPCs and downstream clinical efﬁcacy.Received 1 March 2019; accepted 31 May 2019;
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Retroviral-vector-mediated gene therapy has demonstrated remark-
able clinical success over the past 2 decades.1–13 Disorders of the
hematopoietic system are especially suitable for gene therapy due to
the unique hierarchy of the blood system, with the hematopoietic
stem cell (HSC) being able to reconstitute all blood lineages and
self-renew, providing potential for a lifelong cure. Also, HSCs are
readily accessible from bone marrow or from peripheral blood
upon pharmacological mobilization. The ex vivo modiﬁcation of
hematopoietic stem and progenitor cells (HSPCs) requires in vitro
culture of isolated HSPCs over a period of several days. Applied
culture conditions can signiﬁcantly affect HSC maintenance, expan-
sion, and quality, which, in turn, determine engraftment capacity, dif-134 Molecular Therapy: Methods & Clinical Development Vol. 14 Septe
This is an open access article under the CC BY-NC-ND license (httpferentiation potential, and long-term stem cell performance upon
reinfusion into the patient. Currently, a number of different commer-
cially available culture media manufactured to current good
manufacturing practice (cGMP) are being differentially used across
treatment centers, with little standardization.
While early trials using long terminal repeat (LTR)-driven gammar-
etroviral vectors were overshadowed by the occurrence of insertional
mutagenesis and leukemia caused by the integrated vector,14–18 intro-
duction of the self-inactivating (SIN) design to remove strong
enhancer and promoter elements from the vector’s LTRs,19,20 and/or
switch to the application of lentiviral (LV) vectors,21 which display a
more favorable integration pattern,22 has so far demonstrated safety
in clinical trials.3–5,7,9,10,12,13 Alpharetroviral (ARV) vectors are an
emerging tool for gene therapy and have entered preclinical
testing.23–25 Inherent features of this vector class render them poten-
tially superior to other retroviral vector family members in terms of
safety and, thus, promising for future clinical application. These
features are (1) a short leader region devoid of any major splice sites
and any overlap with retroviral coding regions23 and (2) the most
neutral integration pattern among the different retroviral vectors
developed so far.24–26
Despite the success of retrovirus-based CD34+HSPC gene therapy for
several hematopoietic and non-hematopoietic indications, HSPC
transduction remains challenging and cannot be achieved across all
patients and disease contexts. Some disorders, in particular, require
high copy numbers or a high proportion of gene-modiﬁed cells. As
CD34+ HSPCs are known to be relatively difﬁcult to transduce,mber 2019 ª 2019
://creativecommons.org/licenses/by-nc-nd/4.0/).
AD
CB Figure 1. Media Comparison for CD34+ HSPC
Culture and Expansion
(A) Experimental scheme. Purified CD34+ HSPCs from 2
different HDs were thawed and cultured in X-Vivo 15
(green), SCGM (blue), StemSpan (orange) and HSC Brew
(gray) in the presence of SCF (300 ng/mL), Flt3-L (300 ng/
mL), and TPO (100 ng/mL). Cultures were analyzed daily by
FCM for cell counts and expression of stem cell markers.
Cells were additionally subjected to colony-forming unit
(CFU) assay on day 3 post-thaw. (B and C) Cell counts
assessed with counting beads (B) and percentage of
CD34+CD90+ HSPCsprim (C), determined by FCM at the
indicated time points of culture in the different media. Top:
donor A; bottom: donorB. Error bars indicate themean of 2
independent technical duplicates ± SD; *adjusted p %
0.05, two-way ANOVA with Geisser-Greenhouse correc-
tion. (D) Number of BFU-E, CFU-GM, and CFU-GEMM
colonies in the CFU assay, determined after 2 weeks of
culture in MethoCult. HSC Brew was excluded from CFU
assay due to insufficient cell numbers.
www.moleculartherapy.orghigh MOIs are applied to overcome existing barriers and achieve clin-
ically relevant transduction levels. For these reasons, clinical protocols
would beneﬁt from the identiﬁcation of conditions for enhanced
transduction, allowing greater predictability of dosing and reduced
cost of goods due to more efﬁcient use of vector lots. A continuously
expanding list of small molecule compounds and peptides acting as
transduction enhancers (TEs) have been identiﬁed. Mechanistically,
these can be grouped into two major categories: (1) entry enhancers,
which physically increase co-localization of or lower the repulsion
between viral vector particles and target cells, or which trigger fusion
(RetroNectin,27,28 LentiBOOST,29 protamine sulfate (PS),30 Vectofu-
sin-1,31,32 ViraDuctin, and staurosporine [Stauro]33), and (2) post-
entry TEs, ultimately yielding higher copy numbers of integrated
vector by affecting intracellular processes, such as prostaglandin E2
(PGE2).34 While the beneﬁcial effect of each individual compound
has been previously demonstrated,27–34 a side-by-side comparison
to identify TEs or combinations of TEs with the greatest potential
for CD34+ HSPC transduction remains elusive.
To improve current clinical protocols for ex vivo HSPC clinical gene
therapy, we systematically compared different HSPC culture media
manufactured to cGMP as well as the effects of previously described
TEs on both LV and ARV transduction efﬁciency. The conditions
identiﬁed as most suitable were subsequently applied to a GMP-
compliant manufacturing process of an HSPC advanced therapy
medicinal product (ATMP) for treatment of X-linked severe com-
bined immunodeﬁciency (SCID-X1).
RESULTS
Media Comparison for CD34+ HSPC Culture
To deﬁne optimal HSPC culture conditions, we compared three
different commercially available culture media manufactured to
cGMP (X-Vivo 15, stem cell growth medium [SCGM], and HSC
Brew). For reference, we included the animal-component-free
(ACF) version of StemSpan, used extensively in preclinical research.Molecular ThePuriﬁed CD34+HSPCs from two healthy donors (HDs) were cultured
in the different media according to a standard clinical protocol (Fig-
ure 1A). Cultures were monitored daily by ﬂow cytometry (FCM)
determining cell viability, cell counts, and the HSPC percentage. A
commonmarker proﬁle beyond CD34 to phenotypically discriminate
more primitive HSPCs is CD34+CD90+CD38.35 However, due
to progressive in vitro decrease of CD38 expression as a culture
artifact,36,37 we omitted this marker from our analyses, deﬁning
HSPCsprim by co-expression of the CD34 and the CD90 surface anti-
gens (Figure S1A).
Analysis of cell viability as the percentage of DAPI cells revealed
X-Vivo 15, SCGM, and StemSpan-ACF to be comparable, with the
fraction of live cells exceeding 80% in all cases and with both donors
(Figures S1B and S1C). Regarding cell maintenance and/or expan-
sion, an initial drop in total cell counts was observed with these three
media but recovered from day 2 onward, resulting in expansion
(donor A) ormaintenance (donor B) of total cell numbers (Figure 1B).
No major differences between the media could be observed with
donor B, and differences did not reach signiﬁcance with donor A,
yielding mean counts of 7.7  106 cells with SCGM, 8.4  106 cells
with StemSpan-ACF, and 5.2  106 cells with X-Vivo 15. Manual
cell counts performed on day 3 demonstrated the three media to
perform similarly, with SCGM and StemSpan-ACF yielding slightly
higher cell numbers as compared to X-Vivo 15 (Figure S1D). Deter-
mination of the percentage of CD34+CD90+ HSPCsprim within the
cultures revealed an increase from day 0 to day 3 from 22.6% to
28.4% (X-Vivo 15), to 31.7% (SCGM), and to 27.4% (StemSpan-
ACF) with donor A; and from 8.3% to 24.1% (X-Vivo 15), to 26.5%
(SCGM), and to 23.4% (StemSpan-ACF) with donor B (Figure 1C).
With that, SCGM appeared to be superior to the other media in terms
of HSPCprim percentage. HSPCprim counts were maintained (X-Vivo
15, donor A) or expanded (X-Vivo 15, donor B; SCGM and Stem-
Span-ACF, both donors) over time (Figure S1E). No major differ-
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www.moleculartherapy.orgin X-Vivo 15, SCGM, and StemSpan-ACF cultures. To assess the
colony-forming potential of HSPCs after 3 days of culture in the
different media, cells from donor B were subjected to in vitro
colony-forming unit (CFU) assay. Manual count of colony types
2 weeks post-cell-seeding revealed no major differences in the
numbers of burst-forming unit-erythroid (BFU-E), colony-forming
unit-granulocyte macrophage (CFU-GM), and CFU-granulocyte,
erythrocyte, monocyte, megakaryocyte (CFU-GEMM) (Figure 1D).
In contrast to these three media, live cells were gradually lost upon
culture in HSC Brew with both donors (Figure 1B; Figure S1C),
and the HSPCprim percentage and counts continuously decreased
over time (Figure 1C; Figure S1E). Due to insufﬁcient cell numbers,
HSC Brew was excluded from manual counting and CFU analysis.
Altogether, SCGM was superior to X-Vivo 15 in terms of HSPCprim
percentage but not total cell counts and HSPC maintenance and/or
expansion, while SCGM and StemSpan-ACF performed similarly.
In contrast to StemSpan-ACF, SCGM that is manufactured to
cGMP is currently available and is thus suitable for application in
clinical protocols. Therefore, SCGM was selected for all further
experiments.
TEs Increase CD34+ HSPC Transduction Efficiency with LV and
ARV Vectors
We selected 7 previously described TEs and systematically compared
their effects on retroviral gene transfer and HSPC quality in SCGM.
These included LentiBOOST,29 PGE2,34 PS,30 Vectofusin-1,31,32,38
ViraDuctin, RetroNectin,28 and Stauro33 (Figure S2A). Selection
was also based on the availability of TEs manufactured to cGMP to
allow for rapid translation of ﬁndings into clinical application. Taking
this into consideration, we also included the synthetic, antineoplastic,
clinically used 7-hydroxy derivative of Stauro (OH-Stauro), making 8
TEs in total. As OH-Stauro, to our knowledge, has not yet been tested
as a TE, two different concentrations (referred to as “high” and “low”)
were tested for OH-Stauro and for Stauro.
While having been previously analyzed in combination with LV vec-
tors, TE effects on ARV transduction efﬁciencies have not yet been
determined. Due to the inherent safety features, which make them
attractive for future clinical gene therapy, and the increasing
preclinical use of ARV vectors for modiﬁcation of HSPCs and otherFigure 2. Single Transduction Enhancers Increase Transduction of CD34+ HSP
(A) Schematic representation of the EGFP-encoding alpharetroviral (ARV) and lentiviral
phosphoglycerate kinase promoter; PRE, post-transcriptional regulatory element; DU3
HSPCs from 3HDswere pre-stimulated for 24 h prior to transduction in the presence or a
carried out at a MOI of 20, which is lower than the MOI used with most gene therapy prot
Cells were washed after 24 h and analyzed by FCM1week post-transduction. Donor Cw
of CD34+CD90+ HSPCsprim 1 week post-transduction with LV (C) and ARV (D) vectors a
PGE2, prostaglandin E2; PS, protamine sulfate; Stauro, staurosporine; OH-Stauro, 7-h
treatment (“-” condition) for each donor. (E and F) Total EGFP expression (= normalized p
cells 1 week post-transduction with LV (E) and ARV (F) vectors at a MOI of 20. Vertical b
mean fold increase (ifR1.1) from the four experiments. (G and H) Total EGFP expressio
ARV (H) vectors at a MOI of 20. Vertical bars represent the mean total expression. Nu
experiments.
Molecular Thehematopoietic cell types,24–26,39–41 we sought to identify compounds
that enhance ARV gene transfer in parallel to testing TE effects on
LV gene transfer. We used LV and ARV standard SIN EGFP re-
porter vectors with an identical design of the internal gene expres-
sion unit (Figure 2A). Puriﬁed CD34+ HSPCs from three HDs
were transduced with VSV-G (vesicular stomatitis virus G pro-
tein)-pseudotyped vectors in the presence or absence of the selected
TEs (Figure 2B). In order to investigate any effects on HSPC “stem-
ness,” the percentage of CD34+CD90+ (HSPCsprim) was determined
(Figures 2C and 2D; Figure S2B). Individual TEs had consistent ef-
fects regardless of their combination with LV or ARV vectors and
could be grouped into two categories: (1) causing no (LentiBOOST
and RetroNectin), or only a very mild reduction in the HSPCprim
percentage (PS, Vectofusin-1, Stauro, and OH-Stauro), and (2)
causing a consistent reduction in the HSPCprim percentage (PGE2
and ViraDuctin). PGE2 reduced the HSPCprim percentage to an
average of 66% (Figure 2C) and 76% (Figure 2D) of that of
vehicle-only controls for LV and ARV transduction, respectively.
Individual analysis of CD34 and CD90 antigen expression revealed
the reduction in the HSPCprim percentage to be almost exclusively
resulting from a loss in CD90 expression in all cases (Figures S3A
and S3B).
To determine TE effects on transduction efﬁciency, the percentage of
EGFP+ cells was determined both in the live cell population and in the
HSPCprim fraction (Figures S2B and S3C–S3F). In the absence of TEs,
LV and ARV transduction of HSPCs at a MOI of 20 yielded efﬁ-
ciencies of 38.7% (Figure S3C) and 9.0% (Figure S3D), respectively,
revealing the LV vector to be more potent in our setting than its
ARV counterpart. A preference for transduction of the HSPCprim
fraction was observed with the tested vector batches, reaching
57.0% (LV) and 17.7% (ARV) transduction efﬁciencies in the absence
of TEs (Figures S3E and S3F). Of the 8 selected TEs, 6 increased LV
and 5 elevated ARV transduction efﬁciencies (Figures S3C–S3F).
However, with transduction efﬁciencies exceeding 30% and, thus,
with the occurrence of multiple integrations in a substantial fraction
of transduced cells, TE effects might be partially masked when
analyzing %EGFP+. Therefore, we determined the median ﬂuores-
cence intensity (MFI) of EGFP within the EGFP+ population and
calculated total expression as the product of normalized %EGFP+
andMFI (Figures 2E–2H). This analysis conﬁrmed that 6 of the testedCs with Lentiviral and Alpharetroviral Vectors
(LV) SIN vectors used in this study. R, repeat region; U5, unique 5; hPGK, human
, unique 3 region with self-inactivating deletion. (B) Experimental scheme. CD34+
bsence of single transduction enhancers (TEs) in SCGMplus STF. Transduction was
ocols, allowing for a better observation of TE effects due to a lower transduction rate.
as used in 2 independent experiments for selected conditions. (C and D) Percentage
t a MOI of 20. NTC, non-transduced control; -, no TE or vehicle; DMSO, vehicle only;
ydroxy-staurosporine. Horizontal lines indicate baseline levels in the absence of TE
ercentage of EGFP+ cellsmedian EGFP intensity within the EGFP+ fraction) in live
ars represent the mean total expression. Numbers in boxes above bars indicate the
n in the CD34+CD90+ HSPCprim fraction 1 week post-transduction with LV (G) and
mbers in boxes above bars indicate the mean fold increase (ifR1.1) from the four
rapy: Methods & Clinical Development Vol. 14 September 2019 137
Molecular Therapy: Methods & Clinical DevelopmentTEs increased LV gene transfer to both the live cell (Figure 2E)
and the HSPCprim fraction (Figure 2G). The strongest effect was
obtained with LentiBOOST, achieving a 2.4-fold increase in total
expression within live cells and a 2.7-fold increase within HSPCsprim,
followed by Staurolow and Staurohigh, PGE2, OH-Staurohigh, PS and
Vectofusin-1, and OH-Staurolow. In contrast, no positive effects
were observed with ViraDuctin and RetroNectin. For transduction
using ARV vectors, the same TEs showed beneﬁt on gene transfer
rates as for LV vectors, with the exception of PS, which increased total
expression only with LV but not ARV vectors (Figures 2F and 2H). In
the ARV setting, Staurohigh and Staurolow performed best, increasing
transduction by 2.4- and 2.2-fold, respectively, in the live cell (Fig-
ure 2F) and by 1.6- and 1.7-fold, respectively, in the HSPCprim frac-
tion (Figure 2H), followed by LentiBOOST, OH-Staurohigh and
PGE2, and, ﬁnally, Vectofusin-1. No positive effects were seen with
PS, ViraDuctin, RetroNectin, or OH-Staurolow.
Altogether, HSPC transduction with LV and ARV vectors was
improved by more than 2-fold with the use of a single TE, the stron-
gest effects having been observed with LentiBOOST, Stauro, and
PGE2. Furthermore, the HSPCprim percentage was not affected
upon administration of LentiBOOST and only mildly decreased
with Stauro treatment, while PGE2 supplement led to a pronounced
reduction in HSPCprim percentage.
Combinatorial Use of Selected TEs Further Improves LV CD34+
HSPC Transduction
We next investigated whether the combinatorial use of TEs
would further improve transduction, potentially yielding additive
or synergistic effects. As LV, in contrast to ARV, vectors are
already clinically applied, we focused on LV HSPC transduction
in this set of experiments. The four best performing TEs—Lenti-
BOOST, PGE2, PS, and Staurolow—were selected and co-adminis-
tered in groups of two or three in all possible combinations.
Puriﬁed CD34+ HSPCs from three HDs were transduced with
the VSV-G-pseudotyped, EGFP-expressing LV vector as shown
in Figure 2A. Transduction was performed at a MOI of 20 in
SCGM in the absence or presence of single TEs or their combina-
tions (Figure 3A).
The percentage of CD34+CD90+ (HSPCsprim) was used to determine
“stemness” 1 week post-transduction. As a general observation, the
HSPCprim percentage gradually decreased with increasing numbers
of TEs combined together (Figure 3B). However, the decrease in
“stemness” upon combination of LentiBOOST, PS, and Staurolow
was mild, reaching levels of >80% (two TEs) and of 76% (three
TEs) of that of a no-TE-control. LentiBOOST plus PS performed
best for two TEs combined, with the HSPCprim percentage consti-
tuting 92% that of the non-treated control. In contrast, as with single
use, all combinations including PGE2 reduced the HSPCprim percent-
age more than TE cocktails without PGE2, namely, to 62%–69%
(two TEs) and to 57%–63% (three TEs). Again, the decrease in the
HSPCprim percentage was reﬂected in a reduced CD90 antigen expres-
sion in all cases (Figure S4A).138 Molecular Therapy: Methods & Clinical Development Vol. 14 SepteTransduction efﬁciencies, determined as %EGFP+ 1 week post-trans-
duction, reached 38.8% in live cells in the absence of TEs and was
increased to 47%–69% with single-TE treatment, to 68%–83% with
two TEs, and to even 84%–91% with three TEs (Figure S4B), indi-
cating that TE combination provides additional beneﬁt. Within the
CD34+CD90+ HSPCprim fraction, transduction efﬁciencies were
close to saturation with two TEs and could not be further increased
with three TEs (Figure S4C). As for the single-TE analysis, total
expression was calculated and displayed stronger effects. In live cells,
combinatorial use of two TEs yielded a 2.61- to 3.87-fold increase, and
combinatorial use of three TEs yielded a 4.81- to 5.56-fold increase in
total expression (Figure 3C). Within the HSPCprim fraction, Lenti-
BOOST plus PS and LentiBOOST plus Staurolow were the most efﬁ-
cient among the combinations of two TEs, and the combination of
these compounds (LentiBOOST plus PS plus Staurolow) yielded the
highest increase in total expression among the groups of three TEs
(Figure 3D).
With transduction levels close to saturation at a MOI of 20, a second
set of experiments was performed using a lower MOI of 10 to further
differentiate TE effects. Vector copy number (VCN) analysis was
included as a second readout, performed on day 14 post-transduction
to allow for non-integrated episomal vector copies to be diluted out
prior to analysis (Figure 3A). Transduction efﬁciencies in live cells
could be increased from 8.8% in the absence of TE treatment to up
to 65.7% with three TEs (Figure S4D). As expected, observed TE ef-
fects on %EGFP+ (Figure S4D) and on total expression (Figure 3E)
were much more pronounced in the low-MOI setting. LentiBOOST
plus PS (8.36-fold increase) and PS plus Staurolow (12.5-fold increase)
were most potent among the combinations of two TEs, and Lenti-
BOOST plus PGE2 plus PS (20.4-fold increase) was superior to all
others. When analyzing VCNs, an increase of 1.42- to 3.24-fold was
observed with two TEs, and an increase of 2.32- to 3.77-fold was
observed with three TEs (Figure 3F). VCN analysis mostly reﬂected
the effects seen with total expression analysis, conﬁrming Lenti-
BOOST plus PS and PS plus Staurolow as the most efﬁcient combina-
tions of two TEs. Interestingly, the single use of LentiBOOST and
PGE2 did not increase VCNs, although they achieved the strongest
effects in terms of total expression among the four tested compounds.
In turn, while PS and Staurolow achieved less pronounced effects with
regard to total expression upon single use, they increased VCNs by
1.57- and 1.45-fold, respectively.
Combinatorial Use of LentiBOOST and PS Does Not Cause
Major Alterations in HSPC Gene Expression Profiles
To investigate TE effects on HSPC quality and potential toxicity in
more detail by assessing potential alterations in the transcriptional ac-
tivity of HSPCs after viral transduction and TE addition, we per-
formed whole transcriptome analysis. LentiBOOST and PS were
selected as the best performing and, thus, most attractive TE combi-
nation for clinical use based on (1) total expression in the HSPCprim
fraction upon transduction at a MOI of 20, (2) total expression in live
cells upon transduction at a MOI of 10, (3) VCNs upon transduction




Figure 3. Combination of Transduction Enhancers Increases Lentiviral CD34+ HSPC Transduction over Their Single Use
(A) Experimental timeline. CD34+ HSPCs from 3 HDs were pre-stimulated for 24 h and then transduced with the LV vector depicted in Figure 2A at MOIs of 20 and 10 in the
presence or absence of selected transduction enhancer (TE) combinations in two sets of experiments. Cells were cultured in SCGM plus STF. Cells were washed after 24 h
and analyzed by FCM 1 week post-transduction. Vector copy numbers (VCNs) were determined 2 weeks post-transduction (MOI 10 set of experiments). (B) Percentage of
CD34+CD90+ HSPCsprim 1 week after LV transduction at a MOI of 20. NTC, non-transduced control; -, no TE or vehicle; DMSO, vehicle only; PGE2, prostaglandin E2; PS,
protamine sulfate; Stauro, staurosporine. Horizontal lines indicate baseline levels in the absence of TE treatment (“-” condition) for each donor. Numbers in boxes above the
graph indicate the mean fold change from the three experiments, relative to the “no TE” transduced control. (C and D) Total EGFP expression (= normalized percentage of
EGFP+ cells  median EGFP intensity within the EGFP+ fraction) in the live (C) and in the CD34+CD90+ HSPCprim (D) fraction 1 week after LV HSPC transduction at a MOI
of 20. Vertical bars represent the mean total expression. Numbers in boxes above bars indicate the mean fold increase (ifR1.1) from the three experiments. (E) Total EGFP
expression in live cells 1 week post-LV-HSPC-transduction at a MOI of 10. Vertical bars represent the mean total expression. Numbers above bars indicate the mean fold
increase (ifR1.1) from the three experiments. Note: for 2 (green and orange symbols) of the 3 donors, Stauro treatment was performed for 24 h, including the transduction
period, instead of the 2-h pre-incubation period chosen in previous experiments. (F) Vector copy number (VCN) per diploid cell, determined by real-time qPCR detecting the
post-transcriptional regulatory element (PRE) 2 weeks post-transduction at aMOI of 10. Vertical bars represent themean of three experiments. Numbers in boxes above bars
indicate the mean fold increase. Note that, for 2 (green and orange symbols) of the 3 donors, Stauro treatment was performed for 24 h, including the transduction period,
instead of the 2-h pre-incubation period chosen in previous experiments.
www.moleculartherapy.orgnon-clinical EGFP-reporter vectors. To test the effect of these two
TEs on gene expression proﬁles, puriﬁed CD34+ HSPCs from three
HDs were sorted for the CD34+CD38 population directly afterMolecular Thethe cell thaw to enrich for the stem cell fraction (Figures S5A and
S5B). CD38 was used as a marker, as cells were immediately
characterized without any prior culturing and, thus, without therapy: Methods & Clinical Development Vol. 14 September 2019 139
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Figure 4. LentiBOOST Plus Protamine Sulfate Do Not Cause Major Alterations in HSPC Gene Expression Profiles
(A) Hierarchical clustering of RNA-seq data. NTC, non-transduced and non-TE-treated control; TE, non-transduced control treated with TE only; LV, transduced in the
absence of TE; LV+TE, transduced in the presence of TE. (B) First two components of a principal-component analysis, with percentage of variance associatedwith each axis;
each dot represents a sample, colored according to donor source. (C) List of differentially expressed genes (DEGs) found to be significantly deregulated (adjusted p% 0.05)
for each treatment comparison. (D) Volcano plots of RNA-seq data from three biological replicates; differentially expressed transcripts (adjusted p % 0.05) between
LV-treated or LV+TE-treated and untreated HSPCs are highlighted in red.
Molecular Therapy: Methods & Clinical Developmentrisk of false-CD38-negatives arising as an artifact of prolonged
culture. The percentage of CD34+CD38 cells constituted 14.9%–
26.7% of the total population in all three donors (Figure S5C). After
a 24-h pre-stimulation period, transduction was accomplished using
the LV EGFP vector, shown in Figure 2A, at a MOI of 20 in the pres-
ence or absence of LentiBOOST plus PS. The sorted cells from each
donor were split into the following four conditions: (1) negative con-
trol (untreated; NTC), (2) TE control (TE supplement without LV
transduction), (3) transduction control (LV; transduction in the
absence of TEs), and (4) LV vector transduction in the presence
of TEs (LV+TE). The day after transduction, samples were EGFP
sorted, and RNAwas harvested. As before, TE treatment prominently
improved LV HSPC transduction, elevating the percentage of EGFP+
cells from 61.4% to 98.8% upon TE administration averaged across all
three donors (Figures S5D and S5E).
An unsupervised cluster analysis of the RNA-sequencing (RNA-seq)
samples identiﬁed three main branches corresponding to the different
donor cell sources (Figure 4A). Within each branch, LV-treated or
LV+TE-treated samples did not form distinct clusters, compared with
untreated samples, indicating substantial overlap between the gene
expression proﬁles of treated and untreated samples. Principal-compo-
nent analysis conﬁrmed these results, with donor variability being the
main source of variance in the data (Figure 4B). Using a supervised hi-140 Molecular Therapy: Methods & Clinical Development Vol. 14 Septeerarchical ordering approach, we identiﬁed 107 and 126 genes that var-
ied signiﬁcantly (p % 0.05) between untreated and LV- or LV+TE-
treated samples, respectively (Figure 4C). However, when analyzing
the extent of expression changes, 0 or 19 genes were differentially ex-
pressed byR1.5-fold in LV+TE- or LV-treated samples compared to
untreated samples (Figure 4D; Figure S6). Moreover, Gene Ontology
analysis of differentially expressed genes showed no enrichment for
functional categories, suggesting that the modest transcriptional
changes seenuponHSPC transductionwithorwithoutTEdonot reﬂect
a functional up- or downregulation of speciﬁc cellular pathways. Such
ﬁndings are in keeping with the absence of sample segregation accord-
ing to transduction or TE addition, as observed by the unsupervised
clustering analysis, and indicate that our gene therapy protocol causes
nomajor alterations in the gene expression program of healthy HSPCs.
Combination of LentiBOOST and PS Increases CD34+ HSPC
Gene Transfer Using a Clinical LV Vector under GMP Conditions
We next sought to validate the identiﬁed culture and transduction
conditions in a clinically relevant setting. Thus, selected conditions
were applied in a GMP-compliant ATMP manufacturing process
for SCID-X1.42 Freshly puriﬁed CD34+ HSPCs were transduced in
SCGM with SCID-X1 LV vector in accordance with our clinical pro-
tocol (Figures 5A and 5B).42 LentiBOOST and PS were added during







Figure 5. LentiBOOST Plus Protamine Sulfate Increase Transduction of CD34+ HSPCs with a Clinical-Grade Lentiviral SCID-X1 Vector under GMP
Conditions
(A) Experimental timeline. Fresh CD34+ HSPCswere purified from amobilized leukapheresis and pre-stimulated for 24 h in SCGM supplemented with STF. Transduction was
performed at aMOI of 66.66 (1 108 IG/mL) in the presence or absence of the TEs LentiBOOST and PS in two rounds on consecutive days. Viability was determined regularly
by trypan blue staining and manual cell count. The product was formulated on day 3 post-selection, and cells were analyzed for the expression of stem cell markers by FCM.
An aliquot of the formulated product was thawed and analyzed for the VCN 1week after liquid culture and for CFUs, as well as for the VCN in individual colonies, after 2 weeks
(legend continued on next page)
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Molecular Therapy: Methods & Clinical DevelopmentViability was mildly reduced in the TE-treated culture, as compared
to the control culture, especially on day 3 of the protocol (Figure 5C).
However, day-3 viability within the TE-treated culture was still
acceptable, constituting 87.9%. FCM performed on day 3 of the pro-
cedure identiﬁed 19.8% of CD34+CD90+ HSPCsprim for the control
culture and 16.0% of HSPCsprim for the TE-treated sample (Fig-
ure 5D). The capacity for in vitro proliferation and differentiation
was determined by standard CFU assay (Figure 5A), revealing the
control culture to give a slightly higher number of colonies than the
TE-treated sample (Figure 5E). In order to determine the effects of
TEs on transduction rates, VCNs were assessed through real-time
qPCR. After 7 days of liquid culture (Figure 5A), mean VCNs per
cell of 0.71 and of 4.53 were detected for the control and the
TE-treated samples, respectively, revealing a 6.4-fold increase upon
TE administration (Figure 5F). VCN analysis also showed an increase
of 3.2-fold in individual CFU colonies upon TE treatment, and this
increase was consistent across different colony types (total CFU,
BFU-E, and non-BFU-E) (Figure 5G). Similarly, a 3.4-fold increase
upon TE treatment was observed in the percentage of vector-positive
CFUs (Figure 5H).
The observed increase in the VCN upon TE addition offers the poten-
tial to reduce vector dose or the number of transductions required to
achieve sufﬁcient transduction rates. Using the clinical-grade
SCID-X1 vector batch as before, we tested two further protocols
incorporating the TEs LentiBOOST and PS: (1) only one round of
transduction at the full dose of 1  108 infectious genomes
(IG)/mL and (2) one round of transduction at half the dose, i.e., at
0.5  108 IG/mL (Figure 5I). In contrast to the previous protocol,
the ﬁnal product is formulated 1 day earlier. VCNs in liquid cultures
were signiﬁcantly higher (one transduction at the full dose) or
comparable (one transduction at half the original dose) when
compared to the conventional protocol using two rounds of transduc-
tion at 1  108 IG/mL in the absence of TE (Figure 5J), showing that
TE addition allows for a reduction in vector dose to one fourth the
original amount. In individual CFUs, VCNs were in a range of be-
tween 0.7 and 2.7 copies per cell and were higher upon TE addition
at half and at one fourth of the total vector amount, as compared to
the full vector dose applied in the absence of TE (Figure 5K). Simi-
larly, an increased percentage of vector-positive CFUs was observedof culture inMethoCult (CFU assay). All steps were performed under GMP conditions and
used for the treatment of SCID-X1, with a SIN design to express the interleukin-2 recep
factor 1a promoter; PRE, post-transcriptional regulatory element; DU3, unique 3 region
exclusion. TE, no transduction enhancer; +TE, supplemented with LentiBOOST an
transduction enhancer; +TE, supplemented with LentiBOOST and PS. (E) CFU assay. In
TE, no transduction enhancer; +TE, supplemented with LentiBOOST and PS. (F) Mea
1 week of liquid culture. TE, no transduction enhancer; +TE, supplemented with Len
mean ± SD.TE, no transduction enhancer; +TE, supplemented with LentiBOOST and
real-time qPCR detecting the Psi sequence. (I) The clinical transduction protocol involvin
was tested against two modified protocols entailing the use of the TEs LentiBOOST and
vector dose (0.5  108 IG/mL). VCN determination in liquid culture and CFU assay
supplemented with LentiBOOST and PS. (J) Mean VCNs of the LV Psi sequence per d
Kruskal-Wallis test with Dunn’s multiple comparison. Bars indicate the mean ± SD. (K
centage of vector-positive CFUs in different CFU fractions, determined by real-time qP
142 Molecular Therapy: Methods & Clinical Development Vol. 14 Septeupon TE administration at reduced total vector doses, as compared
to the conventional transduction protocol (Figure 5L).
DISCUSSION
Genetic modiﬁcation of CD34+ HSPCs offers a cure for monogenic
hematological disorders. Despite initial success in a number of disease
contexts, relatively low permissiveness of CD34+HSPCs to gene trans-
fer, patient-to-patient variability, and difﬁcult-to-treat disease con-
texts require the identiﬁcation of strategies to overcome existing bar-
riers and to optimize current procedures toward reliable, context- and
patient-independent, and cost-effective treatment protocols. Innate
barriers limiting gene transfer into HSPCs impose the use of high
MOIs in clinical procedures, which, in most cases, also entails multiple
rounds of viral vector administration and prolonged ex vivo culture. In
this study, we addressed both the aspect of deﬁning suitable ex vivo
culture conditions and the aspect of increasing retroviral gene transfer
into CD34+ HSPCs by conducting a systematic comparison of culture
media and TEs under clinically relevant conditions.
An optimal HSPC culture medium is serum-free and completely
deﬁned, is manufactured to cGMP, and maintains or expands cell
numbers while preserving HSPCs. In a side-by-side comparison, we
revealed SCGM to support the greatest expansion in HSPCprim per-
centage. Using our protocol, SCGM plus hSTF (human stem cell
factor (hSCF), human thrombopoietin (hTPO) , and human Flt3-
Ligand (hFLT3-L) cytokines applied at clinically used concentrations
also allowed efﬁcient LV transduction of CD34+ HSPCs, with around
40% of transduced cells at a MOI of 20. Interestingly, ARV transduc-
tion efﬁciencies were below 10% when applied at the same MOI, sug-
gesting that, although potentially superior in terms of integration
safety proﬁles, ARV vectors may be less efﬁcient in CD34+ HSPC
transduction than LV counterparts.
Use of single TEs potently increased both LV and ARV HSPC trans-
duction. All compounds, except for OH-Stauro (not previously
tested), had been previously identiﬁed to improve LV CD34+ HSPC
transduction and were selected based on these positive results.27–34
Optimally, to be included in clinical procedures, a TE fulﬁlls the
following characteristics: (1) absence of cytotoxicity and preservation
of stem cell quality, (2) positive inﬂuence on transduction, (3)according to GMPprotocols. (B) Schematic representation of the LV vector clinically
tor gamma chain (IL2RG). R, repeat region; U5, unique 5; EF1a, human elongation
with self-inactivating deletion. (C) Percentage of live cells, determined by trypan blue
d PS. (D) Percentage of CD34+CD90+ HSPCsprim on day 3 post-thaw. TE, no
dividual colony types were manually counted after 2 weeks of culture in MethoCult.
n VCN of the LV Psi sequence per diploid cell, determined by real-time qPCR after
tiBOOST and PS. (G) VCN (Psi) in individual CFU colonies. Error bars indicate the
PS. (H) Percentage of vector-positive CFUs in different CFU fractions, determined by
g two rounds of transduction at 1  108 IG/mL in the absence of TE administration
PS, i.e., only one round of transduction at the full vector dose or at half the original
s were performed as shown in Figure 5A. TE, no transduction enhancer; +TE,
iploid cell, determined by real-time qPCR after 1 week of liquid culture. *p% 0.05,
) VCNs (Psi) in individual CFU colonies. Error bars indicate the mean ± SD. (L) Per-
CR detecting the Psi sequence. Error bars indicate the mean ± SD.
mber 2019
www.moleculartherapy.orgavailability as manufactured to cGMP product, and (4) easy applica-
tion. While PGE2 and ViraDuctin treatment lowered the HSPCprim
frequency according to surface markers, and ViraDuctin as well
as RetroNectin administration did not achieve improved LV
HSPC transduction, LentiBOOST, PS, Vectofusin-1, Stauro, and
OH-Stauro all elevated transduction efﬁciencies with minimal detri-
mental effect on HSPCprim content. The greatest increase in LV
HSPC transduction was observed with LentiBOOST. As most TEs
act on the attachment or entry process, they were likely to be appli-
cable to boost not only LV transduction but also that of other retro-
viral family members when using the same entry route or envelope.
Indeed, 4 of the 5 TEs enhancing LV transduction also increased
ARV gene transfer. Interestingly, and in contrast to all other TEs,
PS only stimulated LV but not ARV HSPC transduction, although
both particle types were pseudotyped with VSV-G, suggesting that
vector- or vector-genus-intrinsic characteristics might also play a
role in this context.
Dissecting the individual effects, we could observe preferential effects
for some of the TEs included in our panel on one or several of the
following parameters: (1) transduction efﬁciency, (2) VCN, or (3)
expression level (MFI). LentiBOOST and PGE2 both yielded a strong
increase in transduction efﬁciency, while VCNs were not enhanced.
This suggests that, rather than achieving an absolute enhancement
in transduction, these compounds affect the distribution of vectors
in the cell population, yielding more vector-positive cells but with
less vector copies per cell. An unaltered VCN upon LentiBOOST-
assisted HSPC transduction was likewise observed by others when
applied at similar concentrations.29 We also observed an increased
MFI of EGFP within the EGFP+ population (data not shown, but re-
ﬂected by the total expression) upon administration of LentiBOOST,
a putative entry enhancer. To achieve an increasedMFI in the absence
of an increased VCN, we hypothesize that LentiBOOST has addi-
tional effects beyond the enhancement of fusion between vector par-
ticles and cells that might play a role in elevated expression levels. In
that regard, it would be interesting to compare integration patterns
and explore entry pathways and intracellular trafﬁcking routes, as
well as the accessibility of LV particles to restriction factors in the
presence and absence of LentiBOOST. Another possible explanation
for the differential effect of LentiBOOST on total expression (deter-
mined 1 week post-transduction) and VCNs (determined 2 weeks
post-transduction) is that it, in a transient manner, facilitates vector
entry in the absence of successful integration, with the vector in the
form of extrachromosomal episomes having been diluted out through
cell division prior to VCN analysis. Determination of transduction ef-
ﬁciency at later time points could shed more light on this aspect.
Nevertheless, even at 2 weeks post-transduction, LentiBOOST
increased VCNs in combination with PS over the numbers achieved
with PS alone. Furthermore, Hauber et al.29 demonstrated a consis-
tent increase in LV CD34+ cell transduction efﬁciency at different
time points, including day 12 post-transduction, upon LentiBOOST
supplement, here also in the absence of an increased VCN, pointing
to an altered vector distribution rather than an only transient effect
based on facilitated vector entry without integration.Molecular TheFor clinical gene therapy protocols, it may be beneﬁcial to combine
TEs that differentially affect individual transduction parameters in
order to achieve a balanced increase in both transduction efﬁciency
across the whole cell population and VCN, while avoiding excessively
high VCNs. Furthermore, exerting different mechanisms of action to
overcome innate barriers and enhance transduction, TEs might also
mechanistically complement each other, opening up the possibility
to achieve even greater effects upon their combination. The selected
TEs in this study operate through different mechanisms of action:
PS and ViraDuctin lower the electrostatic repulsion between particles
and target cell membranes;30 RetroNectin physically increases
co-localization of vector particles and target cells;27 PGE2 acts intra-
cellularly by enhancing an as-yet uncharacterized post-entry step;34
Stauro, as a serine/threonine kinase inhibitor, enhances cell entry
by stimulating actin dynamics;33 Vectofusin-1 is an amphipathic pep-
tide helix that promotes both adhesion and fusion between viral
particles and target cells;31,32,43 and LentiBOOST is hypothesized to
act as an entry enhancer.29 The co-administration of TEs has been
previously tested in a very limited number of combinations,29,33,44
and a systematic comparison of different combinations and their ef-
fects has, so far, not been reported. The combination of Stauro and
PGE2 has been described to further increase the transduction efﬁ-
ciency as compared to either compound alone; however, effects on
VCNs diminished in long-term NSG transplants.33 Co-administra-
tion of LentiBOOST and PS did not increase transduction efﬁciency
over the use of LentiBOOST alone; however, with efﬁciencies above
80%, this might have been due to saturation, and VCNs were, indeed,
further increased upon PS addition.29 For systematic, rational combi-
nation of TEs in groups of two or three, we chose compounds that had
yielded the strongest effects on LV HSPC transduction on their single
use and that could be expected to mechanistically complement each
other, including LentiBOOST, PGE2, PS, and Stauro. Indeed, all com-
binations increased the magnitude of effects over their single use, with
a maximum effect in the combinations of two TEs achieved with
LentiBOOST plus PS and with PS plus Stauro. All three compounds
are available as manufactured to cGMP products and are part of clin-
ical protocols already, making these combinations attractive for
immediate clinical translation. In our hands, the combination of
LentiBOOST and PS was slightly superior to all others in terms of
preserving HSPCsprim according to surface markers. Therefore,
LentiBOOST and PS were chosen for the manufacturing of an
ATMP for SCID-X1 and demonstrated a 6.4-fold increase in VCN.
Furthermore, combination of these TEs allowed for a reduction of
the original vector dose by one half and a reduction of the number
of transductions from two rounds to one (i.e., using, in total, one
fourth of the original vector dose) while still yielding increased
VCNs. On this basis, treatment costs for future clinical gene therapy
approaches could be lowered, and ex vivo HSPC culture time be
reduced, which is also likely to positively beneﬁt HSPC quality.
When using reagents and excipients for the GMP manufacture of an
ATMP, it is important to consider the standards met by them and
their availability: PS can be easily obtained as a licensed medicinal
product for human use. LentiBOOST is supplied by SIRION Biotech.rapy: Methods & Clinical Development Vol. 14 September 2019 143
Molecular Therapy: Methods & Clinical DevelopmentFor commercial and clinical use, SIRION licenses the technology. For
non-proﬁt research and clinical development in phase I/II, SIRION
provides a royalty-free license to its technology.
We have deﬁned optimal HSPC culture conditions and provide in-
sights into individual TE effects. These may serve as a guideline for
the rational, context-dependent choice of TEs or their combination
to be included in clinical gene therapy protocols to increase treatment
efﬁcacy, to reduce patient-to-patient variability, to lower treatment




Primary human CD34+ HSPCs were seeded at 1 106 cells per milli-
liter in culture well plates in GMP SCGM (CellGenix, Freiburg,
Germany) supplemented with 1 U/mL penicillin plus 100 mg/mL
streptomycin (GIBCO, Thermo Fisher Scientiﬁc, Rochford, UK),
300 ng/mL hSCF, 300 ng/mL hFlt3-L, and 100ng/mL hTPO (either
manufactured to cGMP from CellGenix or animal-free from Pepro-
Tech, London, UK), referred to as STF.45 For comparison of HSPC
culture media, using the same supplements as described earlier for
SCGM, cells were cultured in X-Vivo 15 (Lonza, Slough, UK) addi-
tionally supplemented with 1% human albumin (Zenalb 20, Bio
Products Laboratory, Herts, UK), in StemSpan-ACF (STEMCELL
Technologies, London, UK) additionally supplemented with 1%
human albumin, or in HSC Brew GMP medium plus HSC Brew
GMP supplement (Miltenyi Biotec, Surrey, UK) additionally supple-
mented with 2% human albumin.
For the GMP experiment, HD CD34+ HSPCs were isolated from
a fresh mobilized leukapheresis (AllCells, Alameda, CA, USA)
following standard immunomagnetic procedure (CliniMACS, Milte-
nyi Biotec). Cells were seeded at 1–1.5  106 cells per milliliter in
SCGM supplemented with 300 ng/mL hSCF, 300 ng/mL hFlt3-L,
and 100 ng/mL hTPO (manufactured to cGMP from CellGenix).
Cells were cultured in VueLife Culture Bags (CellGenix).
CD34+ HSPC Transduction
The TE concentrations used were as recommended in previous
reports: LentiBOOST, 1 mg/mL (SIRION Biotech, Planegg, Ger-
many); PGE2, 10 mM (Cayman Chemical, Cambridge, UK); PS,
4 mg/mL (Thermo Fisher Scientiﬁc); Vectofusin-1, 10 mg/mL (Milte-
nyi Biotec); ViraDuctin, 1 (Cambridge Bioscience, Cambridge,
UK); RetroNectin, 20 mg/mL (TaKaRa Bio Europe, Saint-Germain-
en-Laye, France); and Stauro (Cambridge Bioscience)/7-hydroxy-
stauro (MERCK Chemicals, Watford, UK), 400 nM and 800 nM.
For small-scale TE testing, 1  105 cells were transduced at
1  106 cells per milliliter in 96-well round-bottom plates (100 mL
per well) at a MOI of 20 or of 10. For LentiBOOST-, PGE2-, and
PS-assisted transduction, cells were pelleted and resuspended in
the pre-mixed transduction cocktail composed of complete medium,
TE, and viral vector. Vectofusin-1 and ViraDuctin were used as per
manufacturer’s instructions. For RetroNectin-based transduction,144 Molecular Therapy: Methods & Clinical Development Vol. 14 Septe48-well plates were coated for 2 h with 4 mg RetroNectin per well
(200 mL of a 20 mg/mL stock) and blocked for 30 min at room
temperature with 2% BSA (Sigma-Aldrich, Poole, UK) in PBS
(GIBCO). Plates were washed with Hank’s balanced salt solution
(GIBCO) supplemented with 2.5% of 1 M HEPES (GIBCO). Viral
vector in a total volume of 150 mL per well was added, and plates
were centrifuged for 2 h at 32C and 1,000  g. After centrifugation,
the viral-vector-containing supernatant was removed, and 1  105
cells were added in 200 mL complete medium. For stauro- and
7-hydroxy-stauro-assisted transduction, cells were pre-incubated
with the compounds for 2 h at 37C. Cells were then washed in
SCGM supplemented with penicillin/streptomycin, pelleted for
5 min at 300  g, and resuspended in transduction cocktail consist-
ing of complete SCGM and viral vector. For all protocols, cells were
washed 16–24 h post-transduction and resuspended in fresh com-
plete SCGM.
For the GMP experiment, cells were transduced two consecutive
times after 24 h pre-stimulation. The vector was added to the me-
dia at a concentration of 108 IG/mL, leading to a MOI of 66.6.
The vector that was used, CCL_pEF1a_IL2RGcoWPRE*, was
manufactured to cGMP (Yposkesi, Corbeil-Essonnes, France).42
Transduction was conducted either in the absence or presence of
LentiBOOST and PS at the concentrations stated earlier. After
each transduction cycle (16–18 h), cells were washed and resus-
pended in fresh complete SCGM. After the second transduction,
cells were formulated in a commercial freezing mix containing
5% DMSO (CryoStor CS5, BioLife Solutions, Bothell, WA, USA)
and cryopreserved using a control rate freezer. All steps were per-
formed according to GMP guidelines and using GMP-approved
materials and procedures.
Flow Cytometry
Cells were harvested, washed, and centrifuged for 5 min at
300  g. Pellets were resuspended in sterile-ﬁltered FCM buffer
composed of PBS supplemented with 0.5% BSA and 2 mM
EDTA (Invitrogen, Paisley, UK). Cells were recorded on the BD
LSR II ﬂow cytometer (BD Biosciences, Oxford, UK) using BD
FACSDiva software, and data were analyzed using FlowJo software
(TreeStar., Ashland, OR, USA). The following antibody panel was
used for HSPCprim characterization: APC Mouse anti-CD90
(eBioscience, Thermo Fisher Scientiﬁc, catalog #17-0909-42) and
BV421 Mouse anti-Human CD34 Clone 581 (RUO) (BD Horizon,
BD Biosciences, catalog #562577). Cell counts were determined us-
ing CountBright Absolute Counting Beads (Invitrogen). Live and
dead cells were discriminated using 1 mg/mL DAPI (Sigma-
Aldrich). The percentage of HSPCsprim was determined within
the live-cell fraction in all cases.
For enrichment of CD34+CD38 HSPCs, cells were stained with
BV421 Mouse anti-Human CD34 Clone 581 (RUO) (BD Horizon,
catalog #562577) and APC/Cy7 Mouse anti-Human CD38 Clone
HIT2 (BioLegend, catalog #303534, London, UK) and sorted on a
FACSAria III (BD Biosciences) cell sorter.mber 2019
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Total RNA was isolated using TRIzol (Invitrogen) and the RNeasy
Mini Kit (QIAGEN, Crawley, UK). RNA-seq libraries were prepared
from 50 ng RNA using the NEBNext Single Cell/Low Input RNA
Library Prep Kit for Illumina (New England Biolabs, Hitchin, UK),
and 75-bp single-end sequences were obtained on a NextSeq 500 In-
strument (Illumina, Cambridge, UK). Sequence tags were mapped to
reference genome Hg19 using STAR aligner v2.5.3a,46 and raw read
counts from HTSeq47 were used to estimate transcript levels. Unsu-
pervised principal component analysis was performed on log2-
transformed normalized counts using R (https://www.r-project.org).
We then used DESeq248 to normalize data using size factors or rlog
transformation and to identify signiﬁcant (adjusted p value% 0.05)
differential expression. Functional cluster analysis of differentially ex-
pressed genes was performed using Ingenuity Pathways Analysis
(Ingenuity Systems) to identify the most relevant molecular interac-
tions, functions, and pathways linking them. Sequencing ﬁles have
been deposited into the GEO public database under accession number
GEO: GSE129386.
Statistics
Columns represent the mean of different replicates. Fold induction
was calculated in relation to a non-TE-treated, transduced control.
Fold induction was ﬁrst calculated individually for each donor setting
and then expressed as the mean of the individual fold induction
values. Error bars represent the mean ± SD. Statistical testing was
accomplished using GraphPad Prism software (GraphPad Software,
San Diego, CA, USA) and two-way ANOVA with Geisser-Green-
house correction (*p% 0.05) or Kruskal-Wallis test with Dunn’s mul-
tiple comparison (*p% 0.05).
Ethics Statement
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Information about vector cloning and production, VCN determina-
tion, and CFU assay can be found in Supplemental Materials and
Methods.
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